<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578292</url>
  </required_header>
  <id_info>
    <org_study_id>THALLO (H-14539)</org_study_id>
    <secondary_id>H-14539</secondary_id>
    <nct_id>NCT00578292</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO</brief_title>
  <acronym>THALLO</acronym>
  <official_title>Pilot Study of Allogeneic Stem Cell Transplantation From Unrelated Donors for Patients With Severe Homozygous Beta 0/+ Thalassemia or Severe Variants of Beta 0/+ Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have severe beta-thalassemia or one of the thalassemia variants. Thalassemia is a
      hereditary disease in which the bone marrow produces abnormal red blood cells that have a
      shorter life span than normal red blood cells. Because of that, the patient has chronically
      low red blood cell numbers (anemia) and need regular blood transfusions to help the patient
      feel better and to help prevent damage to important organs such as the heart. The following
      treatments are currently available to patients: lifelong blood transfusions and drugs that
      help remove iron from the body, and long-term antibiotics to prevent infections. These
      treatments are difficult for patients to take, and do not stop the effects of the disease.

      Currently, the only treatment that may cure thalassemia is bone marrow or blood stem cell
      transplantation. Special blood or bone marrow cells from a healthy person might allow the
      bone marrow to create healthy cells, which will replace the abnormal red blood cells of
      thalassemia. There is a lot of experience using special blood or bone marrow cells from a
      healthy brother or sister who is the same HLA (immune) type. For patients who do not have
      such a donor in the family, an unrelated volunteer donor can be used. It is important for the
      patient to realize that this kind of transplant can have more problems than a transplant from
      a brother or sister.

      Because we do not know the long-term effects of this treatment and because this type of
      transplant has not been used often for people with thalassemia, this is a research study. We
      hope, but cannot promise, that the transplanted marrow/stem cells will produce healthy cells
      and the patient will no longer have severe thalassemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To be treated on this study, we will test the blood to check for viruses, including HIV (the
      virus that causes AIDS). If the HIV test is positive, a transplant cannot be done because it
      would be too dangerous for the patient. Secondly, we will do a liver biopsy to determine if
      the liver has been damaged (which can happen from iron overload that develops after many
      transfusions). Too much liver damage could mean that the patient will have a higher risk to
      develop problems with the transplant.

      To participate in this study, the patients also need to have a central line (a thin plastic
      catheter or tube that is placed during surgery into one of the large veins in the neck or
      chest). Central lines are used to give intravenous medications (go directly into the vein) or
      to take blood samples without the patient having to endure frequent needle sticks. Before the
      treatment starts, we will remove a small amount of the bone marrow (back-up bone marrow) and
      store it. The reason for this is that if the donors bone marrow or blood stem cells do not
      grow properly after the transplant and the patients blood counts stay low, we can put the
      patients own bone marrow cells back into their body. This will help the blood counts to
      recover, but this means that the patient will also have thalassemia again.

      To prepare the body for the transplant, the patients own blood forming system has to be
      destroyed and their immune system has to be weakened. To do this, they will be given high
      dose chemotherapy and medications that weaken their immune system (also called a conditioning
      treatment) for 9 days before the transplant. The main chemotherapy drugs used in the
      conditioning treatment are: cyclophosphamide, fludarabine and busulfan. The chemotherapy
      treatment will last 9 days. The patient will be admitted 10 days before the transplant to
      start a medicine to prevent seizures before they receive the first dose of busulfan since one
      of the side effects of busulfan is risk of seizures. First the patient will be given a drug
      called busulfan through the central line every 6 hours starting 9 days before transplant
      (called Day -9) until 6 days before transplant (called Day -6). Starting one day after
      receiving the last busulfan dose (Day -5), they will receive cyclophosphamide, fludarabine
      and Campath IH, which will all be given through the central line once a day for the next four
      days. Campath IH is a special type of protein called an antibody that works against certain
      types of blood cells. Also on Day -5, we will add a drug called MESNA. MESNA is used to
      decrease the side-effects caused by cyclophosphamide.

      One day after the chemotherapy treatment is finished (Say -1) the patient will have a day to
      rest. On Say 0, the patient will receive the bone marrow/stem cells from the donor. Once in
      the bloodstream, the cells will go to the bone marrow and should begin to grow. To help
      prevent a problem call graft-versus-host disease (GVHD), the patient will receive a small
      dose of methotrexate on four different days after transplant. Another drug to help prevent
      GVHD, tacrolimus, will be started 2 days (Day -2) before the transplant and continued for
      approximately one year after the transplant. To tell whether the transplant has &quot;taken&quot; or
      &quot;engrafted&quot;, we will take samples of blood two to three weeks after the transplant.

      The patient will need to be in the hospital for at least 4 weeks after the transplant to make
      sure the transplant has engrafted. To find out how much the treatment has helped them and how
      much it might help other patients, we will do several routine lung, kidney, and liver tests,
      including liver biopsies, after the bone marrow/stem cell transplant. Additionally, we will
      be looking at the immune function. To do this, we will take 30 mL (2 tablespoonfuls) of blood
      every three months for the first year after transplant and then every 6 months during the
      second year after transplant. When possible, the blood that is taken will be taken through an
      existing IV line. However, at times drawing the blood will require another stick with a
      needle. The total amount of blood to be taken will not exceed 12 tablespoonfuls.

      Because bone marrow/stem cell transplant from an unrelated volunteer donor is a new therapy
      for severe thalassemia and because problems may happen months afterward, the patient will
      need to have exams and blood tests done every few months during the first and second year
      following transplantation.

      The patient may still need to use iron removing agents for some time after transplant or
      undergo blood-letting to get rid of the excess iron in the body. During that time, we will
      monitor the amount of iron in the body. Looking at the iron stored in the liver can most
      accurately tell us how much excess iron the patient has in the body. We will do liver
      biopsies once or twice per year if the patient is receiving iron chelation treatment after
      the transplant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stem cell transplant was determined SOC for this disease (study is not relevant)
  </why_stopped>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment Rate After Transplant</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Engraftment is defined as an absolute neutrophil count (ANC) &gt;500/microL x 3 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Stable Mixed Hematopoietic Chimerism (HC)</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Stable hematopoietic chimerism is defined as having 50-99 percent of donor cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Transient Mixed Hematopoietic Chimerism (HC)</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Transient mixed hematopoietic chimerism is defined as any mixed chimerism return to 100 percent donor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Infectious Complications</measure>
    <time_frame>up to day 100</time_frame>
    <description>All AEs and SAEs (including infections) will be collected for evaluation of infectious complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematopoietic Reconstitution</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Hematopoietic: defined as transfusion independence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Immune reconstitution: defined as absolute lymphocyte count (ALC) &gt;1000x10e3/microL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ACUTE GVHD</measure>
    <time_frame>Assessed weekly from Day 0 to day 100</time_frame>
    <description>Acute GVHD is graded by the method of Przepiorka D. et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With CHRONIC GVHD</measure>
    <time_frame>Assessed monthly from month 3 to month 12</time_frame>
    <description>Chronic GVHD is graded by NIH guidelines for chronic GVHD, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3 where 0 means no chronic GVHD, and 3 is the highest stage of chronic GVHD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>up to 2 years post transplant</time_frame>
    <description>Event-free survival is calculated from the date of transplant to the date of graft failure, disease recurrence or death from any cause.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Bone Marrow or Stem Cell Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6</description>
    <arm_group_label>Bone Marrow or Stem Cell Infusion</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m2 Day -5 through Day -2</description>
    <arm_group_label>Bone Marrow or Stem Cell Infusion</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath 1H</intervention_name>
    <description>Per institutional guidelines Days -5 through -2</description>
    <arm_group_label>Bone Marrow or Stem Cell Infusion</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg Days -5 through -2</description>
    <arm_group_label>Bone Marrow or Stem Cell Infusion</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MESNA</intervention_name>
    <description>10 mg/kg x 5 Days -5 through -2</description>
    <arm_group_label>Bone Marrow or Stem Cell Infusion</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with documented diagnosis of severe (transfusion-dependent) homozygous
        b0/+-thalassemia or severe variants of b0/+-thalassemia requiring chronic transfusion
        therapy and iron chelating agents, who fulfill the following conditions:

          1. Patient does not have an HLA genotype-identical donor available and has a 5/6 or 6/6
             matched unrelated donor, or a 5/6 matched related donor available.

          2. Must be between 1 and 16 yrs of age (all Pesaro risk groups).

          3. Patients older than 17 yrs of age must be in Pesaro Risk Class 2 or lower (see
             Appendix B).

          4. Women of childbearing potential must have a negative pregnancy test.

          5. Documentation of compliance with iron chelation, absence or presence of hepatomegaly,
             and presence or absence of hepatic fibrosis prior to transplant (criteria for the
             Pesaro Risk Classification). This information will be obtained by history, physical
             exam and interpretation of liver biopsy results.

          6. Documentation of awareness of alternative treatment options.

        Exclusion Criteria:

          1. Biopsy-proven chronic active hepatitis or fibrosis with portal bridging.

          2. Has previous history of malignancies.

          3. Creatinine clearance &lt; 35 mL/min/1.73 M2.

          4. Severe cardiac dysfunction defined as shortening fraction &lt; 25%.

          5. HIV infection.

          6. Inadequate intellectual capacity to give informed consent (in the case of minors, this
             criteria must be fulfilled by the legal guardian).

          7. Be pregnant, lactating or unwilling to use appropriate birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tami John, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine/Texas Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tami John, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baylor College of Medicine/Texas Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>April 3, 2020</results_first_submitted>
  <results_first_submitted_qc>April 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2020</results_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Tami D. John</investigator_full_name>
    <investigator_title>Assistant Professor, Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>transfusion-dependent</keyword>
  <keyword>homozygous b0/+-thalassemia</keyword>
  <keyword>severe variants of b0/+-thalassemia</keyword>
  <keyword>transfusion</keyword>
  <keyword>iron chelating agents</keyword>
  <keyword>severe</keyword>
  <keyword>transfusion-dependent homozygous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bone Marrow or Stem Cell Infusion</title>
          <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants received allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors.</population>
      <group_list>
        <group group_id="B1">
          <title>Bone Marrow or Stem Cell Infusion</title>
          <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="2" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Engraftment Rate After Transplant</title>
        <description>Engraftment is defined as an absolute neutrophil count (ANC) &gt;500/microL x 3 days.</description>
        <time_frame>up to 30 days</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment Rate After Transplant</title>
          <description>Engraftment is defined as an absolute neutrophil count (ANC) &gt;500/microL x 3 days.</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.69" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stable Mixed Hematopoietic Chimerism (HC)</title>
        <description>Stable hematopoietic chimerism is defined as having 50-99 percent of donor cells.</description>
        <time_frame>1 year post-transplant</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors and had mixed chimerism (MC). Six participants were not evaluable at the time point of assessment for this outcome measure due to death or graft failure or full donor.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable Mixed Hematopoietic Chimerism (HC)</title>
          <description>Stable hematopoietic chimerism is defined as having 50-99 percent of donor cells.</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors and had mixed chimerism (MC). Six participants were not evaluable at the time point of assessment for this outcome measure due to death or graft failure or full donor.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Transient Mixed Hematopoietic Chimerism (HC)</title>
        <description>Transient mixed hematopoietic chimerism is defined as any mixed chimerism return to 100 percent donor.</description>
        <time_frame>1 year post-transplant</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors and had mixed chimerism (MC). Six participants were not evaluable at the time point of assessment for this outcome measure due to death or graft failure or full donor.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Transient Mixed Hematopoietic Chimerism (HC)</title>
          <description>Transient mixed hematopoietic chimerism is defined as any mixed chimerism return to 100 percent donor.</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors and had mixed chimerism (MC). Six participants were not evaluable at the time point of assessment for this outcome measure due to death or graft failure or full donor.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Infectious Complications</title>
        <description>All AEs and SAEs (including infections) will be collected for evaluation of infectious complications.</description>
        <time_frame>up to day 100</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infectious Complications</title>
          <description>All AEs and SAEs (including infections) will be collected for evaluation of infectious complications.</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematopoietic Reconstitution</title>
        <description>Hematopoietic: defined as transfusion independence.</description>
        <time_frame>1 year post-transplant</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for the outcome measure. Two participants were not evaluated at the time point of assessment for this outcome measure due to death or graft failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Hematopoietic Reconstitution</title>
          <description>Hematopoietic: defined as transfusion independence.</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for the outcome measure. Two participants were not evaluated at the time point of assessment for this outcome measure due to death or graft failure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immune Reconstitution</title>
        <description>Immune reconstitution: defined as absolute lymphocyte count (ALC) &gt;1000x10e3/microL</description>
        <time_frame>1 year post-transplant</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for the outcome measure. Two participants were not evaluated at the time point of assessment for this outcome measure due to death or graft failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution</title>
          <description>Immune reconstitution: defined as absolute lymphocyte count (ALC) &gt;1000x10e3/microL</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for the outcome measure. Two participants were not evaluated at the time point of assessment for this outcome measure due to death or graft failure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ACUTE GVHD</title>
        <description>Acute GVHD is graded by the method of Przepiorka D. et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD</description>
        <time_frame>Assessed weekly from Day 0 to day 100</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for acute GVHD. A participant is evaluable for acute GVHD if he/she engrafted and either completed 100 days observation after transplant or experienced acute GVHD.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ACUTE GVHD</title>
          <description>Acute GVHD is graded by the method of Przepiorka D. et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for acute GVHD. A participant is evaluable for acute GVHD if he/she engrafted and either completed 100 days observation after transplant or experienced acute GVHD.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade II-IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With CHRONIC GVHD</title>
        <description>Chronic GVHD is graded by NIH guidelines for chronic GVHD, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3 where 0 means no chronic GVHD, and 3 is the highest stage of chronic GVHD.</description>
        <time_frame>Assessed monthly from month 3 to month 12</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for chronic GVHD. A participant is evaluable for chronic GVHD if he/she engrafted and survived or remained in the study for more than 100 days after transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CHRONIC GVHD</title>
          <description>Chronic GVHD is graded by NIH guidelines for chronic GVHD, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3 where 0 means no chronic GVHD, and 3 is the highest stage of chronic GVHD.</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) and were evaluable for chronic GVHD. A participant is evaluable for chronic GVHD if he/she engrafted and survived or remained in the study for more than 100 days after transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival</title>
        <description>Event-free survival is calculated from the date of transplant to the date of graft failure, disease recurrence or death from any cause.</description>
        <time_frame>up to 2 years post transplant</time_frame>
        <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow or Stem Cell Infusion</title>
            <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Event-free survival is calculated from the date of transplant to the date of graft failure, disease recurrence or death from any cause.</description>
          <population>The analysis included all participants who underwent allogeneic hematopoietic stem cell transplantation (SCT) from unrelated donors.</population>
          <units>probability of event-free survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.33" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Primary BMT studies have a critical toxicity period of 30 days after BMT day 0. During the critical toxicity period the most severe grade of all AEs is captured. Grade 1 and 2 AEs, hematological toxicities, and fevers are excluded. Serious Adverse Events/Unanticipated Problems are reported (excluding hematological toxicities and fevers) until 100 days after BMT day 0.</time_frame>
      <desc>All adverse events were collected using CTCAE 2.0 for the study. For reporting purpose, adverse event terms were converted using CTCAE v4.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bone Marrow or Stem Cell Infusion</title>
          <description>Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor.
Busulfan: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6
Fludarabine: 30mg/m2 Day -5 through Day -2
Campath 1H: Per institutional guidelines Days -5 through -2
Cyclophosphamide: 50 mg/kg Days -5 through -2
MESNA: 10 mg/kg x 5 Days -5 through -2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders-Other: Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders -Other: PRES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomatitis/Pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders-Other: GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders-Other: hepatic VOD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: Parainfluenza virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: CMV reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: Gram negative rods</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: BK virus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other: HSV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Wound-Infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders-Other: Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria (painful urination)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders-Other: Nitrite in urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tami D. John</name_or_title>
      <organization>Baylor College of Medicine/Texas Children's Hospital</organization>
      <phone>832-824-4723</phone>
      <email>tdjohn@texaschildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

